Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours
Capivasertib pharmacokinetics showed moderate between-subject variability, and most covariates assessed had no significant impact. Body weight, dose, concomitant use of paclitaxel, food effect and formulation showed statistically significant effects. However, these were predicted to impact exposure to capivasertib by <20% and were not expected to be clinically relevant. Based on the population pharmacokinetics, no a priori dose adjustment is needed for intrinsic and extrinsic factors.
Authors
- Diansong Zhou (ORCID: https://orcid.org/0000-0002-2673-1069)
- Cath Eberlein (ORCID: https://orcid.org/0000-0002-7357-7789)
- Simon T. Barry (ORCID: https://orcid.org/0000-0002-8511-0588)
- Marie Cullberg (ORCID: https://orcid.org/0000-0003-1697-972X)
- Carlos Fernández‐Teruel (ORCID: https://orcid.org/0000-0002-1473-2267)
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1007/s40262-024-01407-x
- Citations
- 6
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- AstraZeneca
- Astex Pharmaceuticals